https://www.selleckchem.com/
promoter mutation and BRAF V600E mutation is of interest for therapeutic decision making. The presence of a TERT promoter mutation is correlated to metastatic disease. To report long-term outcomes on best-corrected visual acuity (BCVA) and treatment intervals with a treat-and-extend (TE) regimen in patients with neovascular age-related macular degeneration (nAMD). This observational study included treatment-naïve patients with nAMD, treated with aflibercept. A specific TE protocol without a loading phase and predefined exit criteria was administer